Comparing iso-[131] SGMIB-VHH_1028 with a HER2-targeted radiopharmaceutical (under clinical trial), the radiopharmaceutical in this study demonstrated an elevated level of tumor uptake and a reduced accumulation in the kidney. Here, ERBB2 is linked to neoplasm.